Phrixus Pharmaceuticals Announces Funding by DuchenneDashboard

PHRIXUS PHARMACEUTICALS, INC. ANNOUNCES FUNDING BY
DUCHENNEDASHBOARD, LED BY COALITION DUCHENNE, FOR PRECLINICAL STUDIES

Funding extends scope of respiratory studies funded by NIH to cardiac and skeletal (limb)
muscle

ANN ARBOR, Mich. (July 19 2012)
Phrixus Pharmaceuticals, Inc., a specialty pharmaceutical
company focused on innovative therapies for Duchenne muscular dystrophy (DMD) and heart
failure, today announced that it has received $67,374 in sponsored research funding from a
number of DMD parent organization through the DuchenneDashboard. This funding will allow
Phrixus to extend its recent finding that Carmeseal™, its lead product candidate, can be
delivered subcutaneously at very low dose to treat respiratory aspects of DMD to cardiac
indications as well. Phrixus and its collaborators had previously demonstrated that Carmeseal is
effective in pre-clinical cardiac models after intravenous delivery.
“We are excited to be collaborating with Cath Jayasuriya, Founder and President of Coalition
Duchenne, and the other parent organizations through the DuchenneDashboard. The
Dashboard provides an optimal way for us to engage with parents and to fund this important
development work,” said Thomas A. Collet, president and CEO. The organizations that
contributed through the DuchenneDashboard were: Coalition Duchenne, Hope for Gus, JB
Keys, Jett Foundation, Michael’s Cause, Ryan’s Quest, Suneel’s Light, Team Joseph, Two
Smiles One Hope and the Zack Heger Foundation.

read more